Dulaglutide: A Review of a New Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus
Mohamed Teleb, Ngamdu Sumayin, Sarmad Said
Department of Internal Medicine, Texas Tech University Health Science Center, Paul L. Foster School of Medicine, El Paso, TX, USA
Med Sci Rev 2014; 1:18-23
DOI: 10.12659/MSRev.893152
Available online:
Published: 2014-12-02
Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective therapeutic approach to obtain better glycemic control in type-2 diabetes mellitus patients. Various preclinical and clinical studies demonstrated the efficacy in cardiovascular benefits beside tight glycemic control. In September 2014 the Food and Drug Administration (FDA) approved the GLP-1 RA, Dulaglutide, for the treatment of type-2 diabetes mellitus. The series of AWARD (Assessment of Weekly Administration of LY2189265 in Diabetes) studies compared Dulaglutide with other anti-diabetic agents, with promising results, including weight reduction and controlled systolic blood pressure (BP). The safety panel of Dulaglutide demonstrated a tolerable adverse effect profile, mainly gastrointestinal.
Keywords: Awards and Prizes, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Incretins
